30 citations,
January 2008 in “The Aging Male” The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.
30 citations,
July 2001 in “BJUI” Combination therapy improves urinary flow and reduces residual urine, but needs better stent design.
25 citations,
December 2008 in “The Journal of Urology” Short-term finasteride treatment may lower some cell death factors in prostate cancer cells.
23 citations,
June 1999 in “Clinical Therapeutics” Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
22 citations,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
21 citations,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
21 citations,
November 2014 in “Journal of Endocrinological Investigation” Cross-sex hormone therapy is important for managing gender dysphoria and requires careful monitoring and healthcare provider education.
21 citations,
August 1994 in “Clinical endocrinology” 5α-Reductase inhibitors can help treat hair loss, acne, and prostate issues by reducing DHT levels.
20 citations,
June 2017 in “Hormone Molecular Biology and Clinical Investigation” Long-term use of dutasteride for enlarged prostate may worsen blood sugar, cholesterol, and erectile dysfunction.
14 citations,
January 2020 in “Mediterranean Journal of Rheumatology” New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
12 citations,
October 2004 in “Experimental Gerontology” Changes in testosterone and estrogen receptor genes can affect how men age, influencing body fat, hair patterns, and possibly leading to skin disorders.
6 citations,
December 2016 in “Journal of Dermatology” Dutasteride effectively and safely treats male hair loss for over a year.
4 citations,
November 2005 in “The Journal of Urology” Large prostates link to more hair loss.
1 citations,
January 2020 in “Skin appendage disorders” Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.
1 citations,
January 2019 in “PubMed” Baldness score can't be used to predict prostate size.
1 citations,
December 2013 in “Urological Science” A man developed male breast cancer after four years of finasteride treatment for an enlarged prostate.
1 citations,
May 2011 in “Journal of Human Reproductive Sciences” Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.
January 2023 in “Discovery immunology” T cells and bacteria in the gut and skin help maintain health and protect against disease.
October 2021 in “Dermatology reports” The care model improved timely diagnosis and treatment for psoriasis and psoriatic arthritis.
November 2020 in “Elsevier eBooks” Antiandrogens and androgen inhibitors like spironolactone, finasteride, and dutasteride can treat hair loss and skin conditions, but they have risks and side effects, including potential harm to pregnant women and risks of cancer and heart issues. Herbal remedies also have antiandrogenic effects but lack safety validation.
October 2020 in “Cirugía y cirujanos” Obesity is linked to more severe lower urinary tract symptoms.
June 2020 in “Annals of the Rheumatic Diseases” Patients need better information about the risks of long-term steroid use.
January 2019 in “Current research in diabetes & obesity journal” A woman with type 2 diabetes developed alopecia areata, suggesting a link between the two autoimmune conditions.
Men with early balding may have a higher risk of prostate issues, and surgery for prostate cancer has a slight survival benefit over radiation.
February 2012 in “Expert Review of Endocrinology & Metabolism” The document suggests more research is needed to understand the link between baldness and prostate cancer.
September 2011 in “Urology” Biofeedback treatment for dysfunctional voiding in adults showed no symptom improvement.
September 2011 in “Urology” Some patients fail bladder function tests due to lower flow rates and higher remaining urine volumes, but the exact reasons for failure are unclear.
September 2011 in “Urology” The IPP index is linked to storage symptoms and leftover urine, and may help manage urinary tract symptoms.
October 2010 in “International Journal of Dermatology” An 86-year-old man with prostate cancer was diagnosed with a rare, low-grade breast cancer and underwent surgery but declined additional hormone therapy.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.